In our study, the expression levels of CTLA-4, VISTA, and B7-H3 were significantly different in the high and low risk groups, suggesting that our risk model may be closely related to immunotherapy for GC, and that patients with high expression of immune checkpoint genes may be more sensitive to these checkpoint inhibitors. Here, CTLA4 is linked to gastric cancer.